Hypothesis

no significant difference in headache improvement between patients who received Erenumab before Botox and those who received Botox before Erenumab (e.g., reduction in headache days, intensity, or duration)

proportion of patients who respond positively to treatment is the same in both groups OR there is a significant  difference in the proportion of responders in both groups.

Selection

  1. Patients, that recieved Botox to Erenemab (BE)

    Total Patients:604 Patients received Erenumab between 10/2022 – 12/2024

    Prior Botox Treatment & Up to 2 Additional Prophylactics (excluding antibodies) → 51 Patients

    Exclusions: 1 patient diagnosed with New Daily Persistent Headache (NDPH) & received external Botox not following PREEMPT protocol 1 patient received Botox off-label 3 patients received external Botox 20 patients lacked KSK or anamnesis data

Final Study Population: 26 Patients

  1. Patients, that recieved Erenumab to Botox (EB)

    Total Patients:  604 Patients received Erenumab between 10/2022 – 12/2024

    Max. 3 Prophylactics before Erenumab (excluding antibodies) → 377 Patients Stopped Erenumab and transitioned to Botox → 33 Patients

    Exclusions: 2 patients had antibodies before Botox 1 patient received Botox without forehead treatment 4 patients lacked headache data

Final Study Population: 26 Patients

Patients Characteristics

Prophylactics used

Omit first treatment

MHD

MMD

AMD

the End for today